Skip directly to site content Skip directly to page options Skip directly to A-Z link Skip directly to A-Z link Skip directly to A-Z link

Disclaimer: Early release articles are not considered as final versions. Any changes will be reflected in the online version in the month the article is officially released.

Volume 32, Number 4—April 2026

Research Letter

Rickettsia lanei Rickettsiosis, Oregon, USA, 2025

Author affiliation: Public Health Division, Oregon Health Authority, Portland, Oregon, USA (S.G. Ladd-Wilson); Columbia Sands Infectious Diseases, Redmond, Oregon, USA (R.W. Fawcett); Karius., Inc., Redwood City, California, USA (S.Y. Park, S. Venkatasubrahmanyam, M.S. Lindner); Home Town Animal Hospital, Prineville, Oregon, USA (S. Davis); Crook County Health Department, Prineville (A. Spry); Centers for Disease Control and Prevention, Atlanta, Georgia, USA (J. Singleton, S.E. Karpathy, C.D. Paddock)

Suggested citation for this article

Abstract

Using metagenomic sequencing, we identified a patient infected with Rickettsia lanei who was initially diagnosed with Rocky Mountain spotted fever (RMSF), a clinically similar disease caused by infection with R. rickettsii. Our investigation highlights the importance of clinical, epidemiologic, and laboratory partnerships to leverage the discovery of novel pathogens.

Spotted fever group rickettsioses (SFGRs) comprise multiple febrile, rash-associated illnesses caused by various arthropodborne, intracellular Rickettsia bacteria. Rocky Mountain spotted fever (RMSF), the most severe SFGR, was first described in the western United States around the turn of the 20th Century (https://www.niaid.nih.gov/diseases-conditions/rocky-mountain-spotted-fever). For the next ≈100 years, RMSF was considered the only tickborne SFGR in the United States; however, since 2004, investigators have identified additional pathogens causing SFGRs of varying severity that share clinical features with RMSF (13). Cases of RMSF have been described in Oregon, USA, since 1903 (4,5). We describe an Oregon patient infected with the recently characterized pathogen Rickettsia lanei whose illness resembled RMSF.

Figure 1

Rash lesions on a patient with Rickettsia lanei rickettsiosis, Oregon, USA. A) Pink blanching macules involving the trunk. B, C) Scattered petechiae on the lateral aspect of the foot (B) and posterior aspect of the ankle (C).

Figure 1. Rash lesions on a patient with Rickettsia laneirickettsiosis, Oregon, USA. A) Pink blanching macules involving the trunk. B, C) Scattered petechiae on the lateral aspect of the foot...

In July 2025, a >50-year-old man sought care at an emergency department for 7 days of fever, headache, and myalgias that had progressed to altered mental status with acute delirium, intermittent tachypnea, and difficulty walking. He recalled a tick crawling on his body during outdoor activities in eastern Oregon within 2 weeks before disease onset. Physical examination revealed temperature of 39.3°C, respiratory rate 22 breaths/min, heart rate 112 bpm, and blood pressure 133/79 mm Hg. The man had difficulty following commands and with word-finding. A transitory macular rash was identified on his trunk on the evening following admission (Figure 1, panel A).

Laboratory abnormalities included low serum sodium (124 mEq/L, reference range 135–147 mEq/L), elevated aspartate transaminase (73 U/L, reference range 5–40 U/L), and elevated alanine transaminase (88 U/L, reference range 5–41 U/L). A lumbar puncture was performed; cerebrospinal fluid (CSF) revealed elevated leukocytes (36/µL, reference range 0–5/µL) with 60% lymphocytes and elevated protein (69.3 mg/dL, reference range 15–45 mg/dL). Routine cultures of blood and CSF yielded negative results. PCR and serologic tests for an extensive panel of viral, bacterial, and fungal pathogens also returned negative results, except for IgG (but no IgM) for Francisella tularensis.

The patient was treated empirically with intravenous ampicillin, ceftriaxone, and acyclovir. A petechial rash developed on his distal lower extremities (Figure 1, panels B, C). His mental status and transaminase elevations improved over several days, and he became afebrile. He was discharged after 4 days of hospitalization. Plasma was collected at discharge for microbial cell–free DNA (mcfDNA) metagenomic sequencing by using the Karius Spectrum test (Karius, Inc., https://kariusdx.com), which revealed mcfDNA of R. rickettsii at 219 molecules/100 nL.

Figure 2

Sequence similarity of microbial cell-free DNA amplified and sequenced from a patient in Oregon, USA, to multiple Rickettsia spp. The sequences showed highest sequence similarity (99.2% mean identity) to the recently published R. lanei genome assembly (GenBank accession no. CP172233). Means (dark blue lines) and 10th–90th percentiles (light blue shading) of BLAST percentage identity of 967 sequencing reads were calculated for the most similar genome assemblies of related Rickettsia species in a custom microbial sequence database. p values indicated for significant differences between R. lanei and R. rickettsii subsp. californica and R. rickettsii subsp. rickettsii. p values of <10–6 were obtained by nonparametric (Wilcoxon signed-rank) and parametric (Student t) tests. For each pair, we compared the distribution of percentage identity values, penalized for partial alignment, and with lack of alignment filled in with a subthreshold value of 75%.

Figure 2. Sequence similarity of microbial cell-free DNA amplified and sequenced from a patient in Oregon, USA, to multiple Rickettsiaspp. The sequences showed highest sequence similarity (99.2% mean identity) to...

After review by local and state public health officials, and because of the rarity of confirmed RMSF in Oregon, the Oregon Health Authority consulted with the Centers for Disease Control and Prevention, which determined clinical improvement within 11 days in the absence of doxycycline was unusual for classical RMSF. A discussion with medical and scientific staff at Karius, Inc., began and infection with R. lanei was considered; however, the recently assembled genome of R. lanei (6) was not yet publicly available, and the sequenced mcfDNA matched most closely (98%–98.5% average BLAST identity) by research-use only analysis with available genomes of R. rickettsii (Figure 2). Subsequent reanalysis using the since-released R. lanei genome (GenBank accession no. CP172233) showed 99.2% identity with R. lanei (Figure 2). The Centers for Disease Control and Prevention evaluated a convalescent serum specimen obtained 34 days after illness onset and the plasma specimen obtained at discharge by indirect immunofluorescence antibody assay to detect IgG for R. rickettsii. Results revealed reciprocal titers of <32 for the discharge specimen and 2,048 from the convalescent specimen.

Previous case reports of confirmed R. lanei rickettsiosis described several clinical characteristics shared with the patient we report, including fever, headache, myalgias, respiratory distress, altered mental status, hyponatremia, and transaminitis (3). However, other clinical and laboratory abnormalities identified in previous patients, including nausea, vomiting, respiratory failure, coma, and thrombocytopenia, were not identified in our patient. Rash was documented in our patient but for only 1 of the previously described patients. All 3 patients survived, despite delayed administration of doxycycline, which is uncharacteristic of RMSF (7). Those case descriptions suggest that R. lanei rickettsiosis can be clinically variable and shares many, but not all, features with classical RMSF.

Wide geographic variations in severity of RMSF have perplexed investigators since first reports of the disease emerged from the western United States >100 years ago. Milder manifestations of RMSF were described from several western states, including Oregon, characterized by lower fever and a substantially lower case-fatality rate compared with classical RMSF (4,5,810). Other Rickettsia species could cause clinically similar diseases of varying severity and thereby account for historically recognized differences in severity described for RMSF in the western United States. Increasingly sensitive molecular detection methods, including mcfDNA sequencing, and access to expanding collections of whole genomes could aid in detection of otherwise unsuspected pathogens and contribute to a more nuanced understanding of SFGR epidemiology. Multidisciplinary partnerships among regional and federal health authorities, clinicians, and diagnostic laboratories led to recognition of R. lanei rickettsiosis in Oregon and could leverage identification of cases elsewhere. Clinicians should consider R. lanei when diagnosing patients with presumptive RMSF in the western United States, particularly in clinical scenarios that might appear unusual or atypical for classical RMSF.

Mr. Ladd-Wilson is an Electronic Reporting, Infectious Waste, & Administrative Rules manager for the Acute and Communicable Disease Prevention section of the Oregon Public Health Division of the Oregon Health Authority. His research interests focus on surveillance of enteric, prion, and vectorborne diseases.

Top

Acknowledgment

This investigation was funded by the Centers for Disease Control and Prevention’s Epidemiology and Laboratory Capacity Program.

Top

References

  1. Paddock  CD, Sumner  JW, Comer  JA, Zaki  SR, Goldsmith  CS, Goddard  J, et al. Rickettsia parkeri: a newly recognized cause of spotted fever rickettsiosis in the United States. Clin Infect Dis. 2004;38:80511. DOIPubMedGoogle Scholar
  2. Shapiro  MR, Fritz  CL, Tait  K, Paddock  CD, Nicholson  WL, Abramowicz  KF, et al. Rickettsia 364D: a newly recognized cause of eschar-associated illness in California. Clin Infect Dis. 2010;50:5418. DOIPubMedGoogle Scholar
  3. Probert  WS, Haw  MP, Nichol  AC, Glaser  CA, Park  SY, Campbell  LE, et al. Newly recognized spotted fever group Rickettsia as cause of severe Rocky Mountain spotted fever–like illness, northern California, USA. Emerg Infect Dis. 2024;30:134451. DOIPubMedGoogle Scholar
  4. Anonymous . Spotted fever in Oregon. Med Sentinel. 1903;11:38990.
  5. Spencer  WO. Mountain or spotted fever, as seen in Idaho and Eastern Oregon. Med Sentinel. 1907;15:5327.
  6. Paddock  CD, Harris  A, Clark  TR, Bullock  HA, Hecht  JA, Ladner  JT, et al. Rickettsia lanei, sp. nov. (Rickettsiales: Rickettsiaceae), a newly recognized pathogen of humans associated with the rabbit tick, Haemaphysalis leporispalustris (Acari: Ixodidae). Am J Trop Med Hyg. 2025;113:95765. DOIPubMedGoogle Scholar
  7. Kirkland  KB, Wilkinson  WE, Sexton  DJ. Therapeutic delay and mortality in cases of Rocky Mountain spotted fever. Clin Infect Dis. 1995;20:111821.PubMedGoogle Scholar
  8. Stricker  FD. The prevalency and distribution of Rocky Mountain spotted fever in Oregon. Montana State Board of Hlth Spec Bull. 1923;26:18–20.
  9. Wolbach  SB. Studies on Rocky Mountain spotted fever. J Med Res. 1919;41:1–197, 41.
  10. Philip  CB. Rocky Mountain spotted fever. Bull Med Libr Assoc. 1940;29:8692.

Top

Figures

Top

Suggested citation for this article: Ladd-Wilson SG, Fawcett RW, Park SY, Venkatasubrahmanyam S, Lindner MS, Davis S, et al. Rickettsia lanei rickettsiosis, Oregon, USA, 2025. Emerg Infect Dis. 2026 Apr [date cited]. https://doi.org/10.3201/eid3204.251962

DOI: 10.3201/eid3204.251962

Original Publication Date: March 03, 2026

Table of Contents – Volume 32, Number 4—April 2026

EID Search Options
presentation_01 Advanced Article Search – Search articles by author and/or keyword.
presentation_01 Articles by Country Search – Search articles by the topic country.
presentation_01 Article Type Search – Search articles by article type and issue.

Top

Comments

Please use the form below to submit correspondence to the authors or contact them at the following address:

Stephen G. Ladd-Wilson, Oregon Health Authority Public Health Division, Acute and Communicable Disease Prevention, 800 NE Oregon St, Ste 370, Portland, OR 97232, USA

Send To

10000 character(s) remaining.

Top

Page created: February 20, 2026
Page updated: March 03, 2026
Page reviewed: March 03, 2026
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.
file_external